ImmunOs Therapeutics AG Raises CHF 15M in Series A Financing, Co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials
10.12.2019 11:00:00 EET | Business Wire | Press release
ImmunOs Therapeutics AG, a Swiss bio-technology company and leading developer of a next generation innate immunity focused immunotherapy platform for cancer, announced today the closing of a Series A financing of CHF 15 million. The round was co-led by the Basel life sciences venture capital firm BioMedPartners and Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE), with the participation of Redalpine, Schroder Adveq, Wille Finance AG, BERNINA BioInvest Ltd alongside new private and existing investors. The financing will be used to complete the first-in-human trials with the company’s lead agent, iosH2, a potential new cancer treatment for both solid and liquid tumors. The funding will also be used to broaden the company’s novel immunotherapy iosH platform by advancing additional preclinical programs focusing on both cancer and auto-immunity.
“Recent advances in the understanding of the innate immune system’s role in cancer provide a unique opportunity for ImmunOs Therapeutics and our partners. We value the ongoing support of all the current investors and welcome all the Series A round participants, specifically Pfizer Ventures and BioMedPartners, both of whom have demonstrated a strong commitment to the oncology field,” said Sean R. Smith, CEO of ImmunOs Therapeutics AG.
Dr. Osiris Marroquin Belaunzaran, CSO and co-founder, added: “It is with great pleasure to see that our early research based on HLA open conformer modulation of immune cells is advancing toward a clinical drug candidate for human studies. Targeting the innate immune system to modulate the tumor microenvironment has been a key strategy for ImmunOs, and together with foundational approaches targeting the adaptive immune system such as PD-1 antibodies, we aim to produce a strong therapeutic benefit in difficult-to-treat cancer indications."
In conjunction with the financing, ImmunOs Therapeutics has expanded its Board of Directors to include four new members: Dr. Markus Hosang of BioMedPartners; Dr. Michael Baran of Pfizer Inc.; Dr. Reinhard Ambros, former head Novartis Venture Fund; and Dr. Daniel Vasella, former Chairman and CEO Novartis.
Dr. Markus Hosang noted: “At BioMedPartners, we have over the last 15 years very successfully invested in and brought forward several innovative early-stage cancer companies. We got particularly attracted by ImmunOs and its novel approach that also adds to existing treatment modalities and thus has the potential to provide novel medicines to cancer patients who do not obtain a long-term benefit from current therapies.”
Dr. Michael Baran added: “Advances in understanding the role of the innate immune system is opening up opportunities to expand the potential of cancer immunotherapy. Pfizer Ventures is enthusiastic to support this emerging area through our investment in ImmunOs.”
About ImmunOs Therapeutics AG:
ImmunOs Therapeutics AG is a biotechnology company active in the discovery and development of the next generation of novel human immunomodulatory proteins focused on innate immunity. Originally a spin-off company of the University of Zurich and the University of Basel, our mission is to develop novel therapeutics that will improve the lives of patients with serious disease.
ImmunOs Therapeutics AG lead program is a next generation, novel platform of multitasking biologics targeting diverse immunoregulatory receptors that activate anti-tumor responses built upon years of research and development. ImmunOs proteins work directly on the innate immune system. (For more information, please visit www.immunostherapeutics.com)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005042/en/
Contact information
Investor Relations
Wagistrasse 14
8952 Schlieren (Zurich Area), Switzerland
info@immunostherapeutics.com
International Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64 or +49 30 23 63 27 68
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
bet365 Partners with TestMu AI to Accelerate Global Release Velocity with Agentic AI Quality Engineering31.3.2026 20:01:00 EEST | Press release
TestMu AI (Formerly LambdaTest), the world's first full-stack Agentic AI Quality Engineering platform, today announced that Hillside Technology Limited, the technology powerhouse behind global online gambling leader bet365, has adopted its platform to unify software testing and support hundreds of weekly production releases. The global online gaming industry is currently experiencing a massive shift, with the market projected to exceed $150 billion by 2030. As mobile gaming becomes the primary touchpoint for users, the technical complexity of delivering a seamless, low-latency experience has grown exponentially. For industry giants like bet365, the need to validate software across an infinite matrix of hardware, screen resolutions, and OS versions is a mission-critical requirement. This partnership ensures that, as gaming becomes more mobile-centric, bet365 can lead with technical excellence by testing on real-world configurations that mirror its diverse global user base. Founded in 20
IFF Secures First Heart Health Claim for Soy Protein in Australia and New Zealand31.3.2026 17:00:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients and health & biosciences announced today that a new heart health claim for isolated soy protein has been accepted by the Food Standards Australia New Zealand (FSANZ). The approval enables food and beverage manufacturers in Australia and New Zealand to link soy protein consumption with healthy blood cholesterol levels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330523416/en/ First heart health claim approved for soy protein in Australia and New Zealand. “For decades, IFF has invested in the science behind soy protein and its role in supporting cardiovascular health,” said Tony Andrew, vice president of protein solutions for IFF Food Ingredients. “This approved claim validates years of rigorous research and collaboration. With our deep expertise in ingredient science, application and scale, we are well-positioned to help our customers translate th
Andersen Consulting Strengthens Capabilities with Addition of Lukkap31.3.2026 16:30:00 EEST | Press release
Andersen Consulting adds collaborating firm Lukkap, a consultancy focused on experience-driven capabilities aligned with clients’ evolving people, customer, and digital transformation needs. Founded in 2009 and headquartered in Spain, Lukkap delivers integrated solutions that help organizations transform how they serve customers, engage employees, and unlock value through behavioral insights and data analytics. The firm’s multidisciplinary approach spans customer journey redesign, high-impact employee experience programs, talent and leadership development, predictive analytics, and comprehensive outplacement and transition services. Lukkap works across sectors — including healthcare, pharmaceutical, consumer goods, retail, finance, and banking — to build human-centered strategies that drive measurable business results. “By combining our experience-led methodology with Andersen Consulting’s global platform, we can accelerate the way organizations approach customer experience,” said Albe
Sub-Q Bionics Closes $1.5M Pre-Seed Round to Advance Next-Generation Solution for Lymphedema Care31.3.2026 16:26:00 EEST | Press release
Sub-Q Bionics, a medical device company developing next-generation solutions to improve care for patients living with lymphedema, today announced the successful close of its $1.5 million pre-seed funding round. The round includes investment from Mayo Clinic and Yeda, the technology transfer company of the Weizmann Institute of Science, as well as several private investors. The Israel Innovation Authority also provided matching funds. The funding will enable Sub-Q Bionics to continue to develop its novel bionic lymph node technology designed to transform how lymphedema is managed, based on scientific innovations from the Weizmann Institute and Shamir Medical Center. The system aims to provide a solution to manage fluid with a subcutaneous implant that will allow patients freedom of movement, automatic fluid management and reduction of symptoms such as pain and swelling. Lymphedema affects millions of patients worldwide, especially breast cancer survivors, and remains significantly under
HTEC Achieves SOC 2 Type II Attestation, Reinforcing Commitment to Client Trust31.3.2026 16:25:00 EEST | Press release
HTECtoday announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331132225/en/ HTEC today announced that it has successfully achieved a SOC 2 Type II attestation, audited by Deloitte, demonstrating the company’s commitment to maintaining high standards in security, availability, and confidentiality. For clients, this means working with a technology partner whose practices are standardized, consistently executed, and independently verified over time. It reflects a level of operational maturity where security, reliability, and data protection are built into every engagement. Achieving this standard required coordinated effort across the entire organization. Compliance, engineering, delivery, security, IT, legal, and people t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom